Akebia Therapeutics (AKBA) Operating Expenses (2013 - 2026)

Akebia Therapeutics (AKBA) has 14 years of Operating Expenses data on file, last reported at $45.9 million in Q1 2026.

• On a quarterly basis, Operating Expenses rose 26.94% year-over-year to $45.9 million in Q1 2026; TTM through Mar 2026 was $183.0 million, a 23.86% increase from a year earlier, with the FY2025 full-year figure at $173.2 million, up 17.47% from the prior year.
• Operating Expenses for Q1 2026 stood at $45.9 million, down from $53.6 million in the prior quarter.
• Over the last five years, Operating Expenses for AKBA reached as high as $88.8 million in Q1 2022 and fell as low as $35.3 million in Q2 2024.
• Historically, Operating Expenses has averaged $48.3 million across 5 years, with a median of $44.9 million in 2025.
• Across the five-year window, Operating Expenses slumped 48.89% in 2023 and surged 32.64% in 2025, its largest moves.
• Year by year, Operating Expenses stood at $64.1 million in 2022, then slumped by 43.58% to $36.2 million in 2023, then grew by 11.84% to $40.4 million in 2024, then jumped by 32.64% to $53.6 million in 2025, then declined by 14.34% to $45.9 million in 2026.
• Per Business Quant data, the three most recent Operating Expenses figures were $45.9 million in Q1 2026, $53.6 million in Q4 2025, and $44.9 million in Q3 2025.